News & Media
Main Menu
Presentations
- All PRESENTATIONS
- AZP-3813
- Eneboparatide (AZP-3601)
All PRESENTATIONS
- All PRESENTATIONS
- AZP-3813
- Eneboparatide (AZP-3601)
Eneboparatide (AZP-3601)
Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States. AMCP Nexus 2023 Poster.
Written by
Dan Hennings
Eneboparatide (AZP-3601)
Eneboparatide, A Novel Investigational PTH1R Agonist, Maintains Calcium Homeostasis Without Deleterious Effects on Bone. ASBMR 2023 Poster
Written by
jpoly4
Eneboparatide (AZP-3601)
Skeletal effects of hypoparathyroidism (HypoPT); data from the Canadian National Hypoparathyroidism Registry (CNHR). ASBMR 2023 Poster
Written by
jpoly4
Eneboparatide (AZP-3601)
Cohorte Épi-Hypo : données rénales et osseuses en vie réelle en France. SFE 2023 Presentation.
Written by
Dan Hennings
Eneboparatide (AZP-3601)
The kidney of the patient with hypoparathyroidism: Effect of eneboparatide, a new agonist of the PTH receptor 1. SFE 2023 Presentation.
Written by
Dan Hennings
Upcoming events
26th European Congress of Endocrinology (ECE)
Date: May 11-14, 2024 (Stockholm, Sweden)
World Hypoparathyroidism Awareness Day
Date: June 1, 2024
2024 Endocrine Society Meeting (ENDO)
Date: June 1-4, 2024 (Boston, MA)
BIO International Convention
Date: June 3-6, 2024 (San Diego, CA)
American Society for Bone and Mineral Research 2024 Annual Meeting (ASBMR)
Date: September 27-30, 2024 (Toronto, Canada)
40th Congress of the French Society of Endocrinology
Date: October 16-18, 2024 (Clermont-Ferrand, France)
Acromegaly Awareness Day
Date: November 1, 2024
Social Updates
TWITTER